ArticleOncotarget2018

Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia.

Bhavani Gopalakrishnan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.